SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
CNSY reported Third Quarter 2026 results. The price and volatility reaction is pending.
CNSYearnings

Earnings reactions, page 2

Cerenome, Inc. (CNSY) Q3 FY2026 earnings

November 14, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue was $0.7 million for the third quarter of 2026.
  • Cost of revenue was $0.9 million for the third quarter of 2026.
  • Research and development expense was $2.1 million for the third quarter of 2026.
  • Selling, general and administrative expense was $5.2 million for the third quarter of 2026.
  • Operating loss was $7.5 million for the third quarter of 2026.
  • Net loss was $8.7 million, or $1.14 per share, for the third quarter of 2026.

Notes

During the quarter, Plus Therapeutics rebranded as Cerenome.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →